ClinicalTrials.gg
Active, not recruitingNCT03157128LIBRETTO-001Updated Apr 16, 2026Results posted

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

A Phase 1/2 interventional study of LOXO-292 in Non-Small Cell Lung Cancer, Medullary Thyroid Cancer and Colon Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 85 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
857
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company — 6 open to participants now, 20 under way, 6 of them phase 3. Carcinoma, Non-Small-Cell Lung · Eli Lilly and Company.

Enrollment
8th of 139
857 · median 109
Started
2017
with 1 other
Phase 1/2
13 of 147
none open now
Primary completion
2025-02
later than 6 of 19 live
Registered
121st of 147
by date

Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 8th largest by enrollment of the 139 interventional ones that give a count, is one of 2 that started in 2017, is one of 13 in phase 1/2, reaches primary completion later than 6 of the 19 other live ones, and was the 121st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, or all of them as a file.
02

Study summary

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

Read the detailed description

This is an open-label, multi-center Phase 1/2 study in participants with advanced solid tumors, including RET fusion-positive solid tumors, MTC, and other tumors with RET activation. The trial will be conducted in 2 parts: Phase 1 (dose escalation - completed) and phase 2 (dose expansion). Participants with advanced cancer are eligible if they have progressed on or are intolerant to available standard therapies, or no standard or available curative therapy exists, or in the opinion of the Investigator, they would be unlikely to tolerate or derive significant clinical benefit from appropriate standard of care therapy, or they declined standard therapy. A dose of 160 milligrams (mg) twice a day (BID) has been selected as the recommended phase 2 dose (RP2D). Approximately 875 participants with advanced solid tumors harboring a RET gene alteration in tumor and/or blood will be enrolled to one of six phase 2 cohorts:

  • Cohort 1: Advanced RET fusion positive solid tumor other than NSCLC or thyroid cancer for participants who progressed on or intolerant to first line therapy (open)
  • Cohort 2: Advanced RET fusion positive solid tumor other than NSCLC or thyroid cancer for treatment naïve participants (open)
  • Cohort 3: Advanced RET-mutant MTC participants who progressed on or intolerant to first line therapy (closed)
  • Cohort 4: Advanced RET-mutant MTC participants who are treatment naïve (closed)
  • Cohort 5: Advanced RET-altered solid tumor for participants other than NSCLC or thyroid cancer and RET-mutant MEN2 spectrum tumors (e.g. pheochromocytoma) otherwise ineligible for cohorts 1-4. See details in inclusion/exclusion criteria (open)
  • Cohort 6: Participants otherwise eligible for Cohorts 1-5 who discontinued another RET inhibitor due to intolerance may be eligible with prior Sponsor approval (closed)
03

Conditions studied

  • Non-Small Cell Lung Cancer
  • Medullary Thyroid Cancer
  • Colon Cancer
  • Any Solid Tumor

Keywords

  • LOXO-292
  • KIF5B-RET
  • M918T
  • CCDC6-RET
  • RET-PTC1
  • NCOA4-RET
  • RET-PTC
  • RET-PTC3
  • RET-PTC4
  • PRKAR1A-RET
  • RET-PTC2
  • GOLGA5-RET
  • RET-PTC5
  • ERC1-RET
  • KTN1-RET
  • RET-PTC8
  • HOOK3-RET
  • PCM1-RET
  • TRIM24-RET
  • RET-PTC6
  • TRIM27-RET
  • TRIM33-RET
  • RET-PTC7
  • AKAP13-RET
  • FKBP15-RET
  • SPECC1L-RET
  • TBL1XR1-RET
  • BCR-RET
  • FGRF1OP-RET
  • RFG8-RET
  • RET-PTC9
  • ACBD5-RET
  • MYH13-RET
  • CUX1-RET
  • KIAA1468-RET
  • FRMD4A-RET
  • SQSTM1-RET
  • AFAP1L2-RET
  • PPFIBP2-RET
  • EML4-RET
  • PARD3-RET
  • G533C
  • C609F
  • C609G
  • C609R
  • C609S
  • C609Y
  • C611F
  • C611G
  • C611S
  • C611Y
  • C611W
  • C618F
  • C618R
  • C618S
  • C620F
  • C620R
  • C620S
  • C630R
  • C630Y
  • D631Y
  • C634F
  • C634G
  • C634R
  • C634S
  • C634W
  • C634Y
  • K666E
  • E768D
  • L790F
  • V804L
  • V804M
  • A883F
  • S891A
  • R912P
  • CLIP1-RET
  • Y806C
  • RET fusion
  • RET alteration
  • RET mutation
  • RET rearrangement
  • RET translocation
  • Neoplasms by Site
  • Neoplasms
  • Non-Small Cell Lung Cancer
  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Cancer of Lung
  • Cancer of the Lung
  • Lung Cancer
  • Neoplasms, Lung
  • Neoplasms, Pulmonary
  • Pulmonary Cancer
  • Pulmonary Neoplasms
  • Respiratory Tract Neoplasms
  • Lung Diseases
  • Respiratory Tract Diseases
  • Carcinoma, Bronchogenic
  • Bronchial Neoplasms
  • Medullary Thyroid Cancer
  • Papillary Thyroid Cancer
  • Thyroid Diseases
  • Thyroid Neoplasms
  • Cancer of the Thyroid
  • Cancer of Thyroid
  • Neoplasms, Thyroid
  • Thyroid Ademona
  • Thyroid Cancer
  • Thyroid Carcinoma
  • Endocrine System Diseases
  • Endocrine Gland Neoplasms
  • Head and Neck Neoplasms
  • Thoracic Neoplasms
  • CNS tumor
  • Primary CNS tumor
  • Cancer of Colon
  • Cancer of the Colon
  • Colon Cancer
  • Colon Neoplasms
  • Colonic Cancer
  • Neoplasms, Colonic
  • Malignant tumor of Breast
  • Mammary Cancer
  • Mammary Carcinoma, Human
  • Mammary Neoplasm, Human
  • Neoplasms, Breast
  • Tumors, Breast
  • Human Mammary Carcinoma
  • Malignant Neoplasm of Breast
  • Breast Carcinoma
  • Breast Tumors
  • Cancer of the Breast
  • Breast Neoplasms
  • Breast Cancer
  • RET Inhibitor
  • MTC
  • NSCLC
  • selpercatinib
  • neo-adjuvant treatment in early stage NSCLC
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

For Phase 1:

  • Participants with a locally advanced or solid tumor that:
  • Has progressed on or is intolerant to standard therapy, or
  • For which no standard therapy exists, or in the opinion of the Investigator, are not candidates for or would be unlikely to tolerate or derive significant clinical benefit from standard therapy, or
  • Decline standard therapy
  • Prior multikinase inhibitors (MKIs) with anti-RET activity are allowed
  • A RET gene alteration is not required initially. Once adequate PK exposure is achieved, evidence of RET gene alteration in tumor and/or blood is required as identified through molecular assays, as performed for clinical evaluation
  • Measurable or non- as determined by 1.1 or RANO as appropriate to tumor type
  • (ECOG) score of 0, 1, or 2 or Lansky Performance Score (LPS) greater than or equal to (≥) 40 percent (%) (age less than [\<] 16 years) with no sudden deterioration 2 weeks prior to the first dose of study treatment
  • Adequate hematologic, hepatic and renal function
  • of at least 3 months

For Phase 2: As for phase 1 with the following modifications:

  • For Cohort 1: Participants must have received prior standard therapy appropriate for their tumor type and stage of disease, or in the opinion of the Investigator, would be unlikely to tolerate or derive clinical benefit from appropriate standard of care therapy
  • Cohorts 1 and 2:

    • Enrollment will be restricted to participants with evidence of a RET gene alteration in tumor
    • At least one measurable lesion as defined by RECIST 1.1 or RANO, as appropriate to tumor type and not previously irradiated
  • Cohorts 3 and 4: Enrollment closed
  • Cohort 5:

    • Cohorts 1-4 without measurable disease
    • MCT not meeting the requirements for Cohorts 3 or 4
    • MTC syndrome spectrum cancers (e.g., MTC, pheochromocytoma), cancers with neuroendocrine features/differentiation, or poorly differentiated thyroid cancers with other RET alteration/activation may be allowed with prior Sponsor approval
    • cfDNA positive for a RET gene alteration not known to be present in a tumor sample
  • Cohort 6: Participants who otherwise are eligible for Cohorts 1, 2 or 5 who discontinued another RET inhibitor may be eligible with prior Sponsor approval
  • Cohort 7: Participants with a confirmed stage IB-IIIA NSCLC and a RET fusion; determined to be medically operable and tumor deemed resectable by a thoracic surgical oncologist, without prior systemic treatment for NSCLC

Key Exclusion Criteria (Phase 1 and Phase 2):

  • Phase 2 Cohorts 1 and 2: an additional known oncogenic driver
  • Cohorts 3 and 4: Enrollment closed
  • Cohorts 1, 2 and 5: prior treatment with a selective RET inhibitor Notes: Participants otherwise eligible for Cohorts 1, 2, and 5 who discontinued another selective RET inhibitor may be eligible for Phase 2 Cohort 6 with prior Sponsor approval
  • agent or anticancer therapy (including chemotherapy, biologic therapy, immunotherapy, anticancer Chinese medicine or other anticancer herbal remedy) within 5 half-lives or 2 weeks (whichever is shorter) prior to planned start of LOXO-292 (selpercatinib). In addition, no concurrent investigational anti-cancer therapy is permitted Note: Potential exception for this exclusion criterion will require a valid scientific justification and approval from the Sponsor
  • Major surgery (excluding placement of vascular access) within 2 weeks prior to planned start of LOXO-292 (selpercatinib)
  • Radiotherapy with a limited field of radiation for palliation within 1 week of planned start of LOXO-292 (selpercatinib), with the exception of participants receiving radiation to more than 30% of the bone marrow or with a wide field of radiation, which must be completed at least 4 weeks prior to the first dose of study treatment
  • Any unresolved toxicities from prior therapy greater than (CTCAE) Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy
  • Symptomatic primary CNS tumor, metastases, , or untreated spinal cord compression. Participants are eligible if neurological symptoms and CNS imaging are stable and dose is stable for 14 days prior to the first dose of LOXO-292 (selpercatinib) and no CNS surgery or radiation has been performed for 28 days, 14 days if stereotactic radiosurgery (SRS)
  • active cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of LOXO-292 (selpercatinib) or prolongation of the corrected (QTcF) greater than (>) 470 milliseconds (msec)

    • Participants with implanted pacemakers may enter the study without meeting QTc criteria due to nonevaluable measurement if it is possible to monitor for QT changes.
    • Participants with bundle branch block may be considered for study entry if QTc is appropriate by a formula other than Fridericia's and if it is possible to monitor for QT changes.
  • Required treatment with certain strong cytochrome P450 3A4 () inhibitors or inducers and certain prohibited concomitant medications
  • Phase 2 Cohort 7 ( treatment): Participant must not have received prior systemic therapy for NSCLC.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
857 participants (actual)

Study arms

  • Experimental
    Phase 1: 20 mg Selpercatinib QD

    Participants received Selpercatinib 20 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

  • Experimental
    Phase 1: 20 mg Selpercatinib BID

    Participants received Selpercatinib 20 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

  • Experimental
    Phase 1: 40 mg Selpercatinib BID

    Participants received Selpercatinib 40 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

  • Experimental
    Phase 1: 60 mg Selpercatinib BID

    Participants received Selpercatinib 60 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

  • Experimental
    Phase 1: 160 mg Selpercatinib QD

    Participants received Selpercatinib 160 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

  • Experimental
    Phase 1: 80 mg Selpercatinib BID

    Participants received Selpercatinib 80 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

  • Experimental
    Phase 1: 120 mg Selpercatinib BID

    Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

  • Experimental
    Phase 1: 160 mg Selpercatinib BID

    Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

  • Experimental
    Phase 1: 200 mg Selpercatinib BID

    Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

  • Experimental
    Phase 1: 240 mg Selpercatinib BID

    Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

  • Experimental
    Phase 2, Cohort 1: RET Fusion Solid Tumor

    Participants with Rearranged during transfection (RET) Fusion solid tumor progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

  • Experimental
    Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy

    Participants with RET Fusion solid tumor without standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

  • Experimental
    Phase 2, Cohort 3: RET Mutant MTC

    Participants with RET mutant medullary thyroid cancer (MTC) progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

  • Experimental
    Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy

    Participants with RET mutant MTC without prior standard first line therapy or other kinase inhibitor(s) with anti-RET activity received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

  • Experimental
    Phase 2, Cohort 5: Advanced RET Altered Solid Tumor

    Participants with RET altered solid tumor (cohorts 1-4, disease not measurable; MTC not eligible for Cohort 3 or 4; MTC syndrome spectrum cancer; circulating free tumor DNA \[cfDNA+\] for RET alteration not known to be present in tumor) received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

  • Experimental
    Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants

    Participants otherwise eligible for Cohorts 1-5 who discontinued other RET inhibitors received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

    Drug: LOXO-292

Interventions

  • Oral LOXO-292

    Also known as: Selpercatinib, LY3527723

06

What researchers measure

Primary outcomes

  1. Phase 1: Maximum Tolerated Dose (MTD)

    The MTD is defined as the highest dose level at which none of the first 3 treated patients, or not more than 1 of the first 6 treated patients, experiences a DLT. A DLT is any adverse events that starts on or after first administration of study drug, as defined by National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. * Any Grade(G) ≥3 nonhematologic toxicity, excluding * G3 AST, ALT, and/or total bilirubin elevation for \<7 days. * G3 neutropenia \<7 days * G3 thrombocytopenia without clinically significant bleeding * G3 or G4 lymphopenia. * First occurrence of G3 or G4 electrolyte abnormalities * G3 fatigue, weakness, nausea; other manageable constitutional symptom * G3 or G4 vomiting or diarrhea that lasts for \<48hours with antiemetic/antidiarrheal medication in case of G3 and \<24 hours in case of G4 * G4 manageable constitutional symptom.

    Time frame: Cycle 1 (cycle length = 28 days)

  2. Phase 1: Recommended Phase 2 Dose (RP2D)

    Phase 1: RP2D

    Time frame: Cycle 1 (cycle length = 28 days)

  3. Phase 2: Objective Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment

    Objective Response Rate was defined as the percentage of participants with best overall response of confirmed response (CR), or Partial response (PR). Response was confirmed by a repeat assessment no less than 28 days. * CR is defined as disappearance of all target lesions. * PR is defined as at least a 30% decrease in the sum of diameter (LD for non-nodal lesions and short axis diameter \[SAD\] for nodal lesions) of target lesions, taking as reference the baseline sum LD. ORR was assessed by independent review committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 95% confidence interval was calculated using Clopper-Pearson method.

    Time frame: Approximately for up to 7 years 8 months

Secondary outcomes

  1. Phase 1: Number of Participants With a Treatment-Related Adverse Event(s) (TRAE[s])

    Phase 1: Number of Participants with a TRAE(s) is reported.

    Time frame: Up to 28 days

  2. Phase 1: Number of Participants With an Abnormal Laboratory Values

    Time frame: Up to 28 days

  3. Phase 2: Overall Response Rate (ORR) Based on RECIST 1.1 or RANO, as Appropriate to Tumor Type

    Phase 2: ORR based on RECIST 1.1 or RANO, as Appropriate to Tumor Type

    Time frame: Approximately for up to 9 years 8 months

  4. Phase 2: ORR (by Investigator)

    Phase 2: ORR (by Investigator)

    Time frame: Approximately for up to 9 years 8 months

  5. Phase 2: Best Change in Tumor Size From Baseline (by IRC and Investigator)

    Phase 2: Best Change in Tumor Size from Baseline (by IRC and Investigator)

    Time frame: Approximately for up to 9 years 8 months

  6. Phase 2: Duration of Response (DOR; by IRC and Investigator)

    Phase 2: DOR (by IRC and Investigator)

    Time frame: Approximately for up to 9 years 8 months

  7. Phase 2: Central Nervous System (CNS) ORR (by IRC)

    Phase 2: CNS ORR (by IRC)

    Time frame: Approximately for up to 9 years 8 months

  8. Phase 2: CNS DOR (by IRC)

    Phase 2: CNS DOR (by IRC)

    Time frame: Approximately for up to 9 years 8 months

  9. Phase 2: Time to Any and Best Response (by IRC and Investigator)

    Phase 2: Time to Any and Best Response (by IRC and Investigator)

    Time frame: Approximately for up to 9 years 8 months

  10. Phase 2: CBR (by IRC and Investigator)

    Phase 2: CBR (by IRC and Investigator)

    Time frame: Approximately for up to 9 years 8 months

  11. Phase 2: PFS (by IRC and Investigator)

    Phase 2: PFS (by IRC and Investigator)

    Time frame: Approximately for up to 9 years 8 months

  12. Phase 2: Overall Survival (OS)

    Phase 2: OS

    Time frame: Approximately for up to 9 years 8 months

  13. Phase 2: Percentage of Participants With Any Serious Adverse Event (SAE[s])

    Phase 2: Percentage of Participants with any SAE(s)

    Time frame: Approximately for up to 9 years 8 months

  14. Phase 2: Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve of LOXO-292 (Selpercatinib)

    Phase 2: PK: AUC of LOXO-292 (Selpercatinib)

    Time frame: Cycle 5 Day 1 (Cycle = 28 days)

  15. Phase 2: PK: Maximum Concentration (Cmax) of LOXO-292 (Selpercatinib)

    Phase 2: PK: Cmax of LOXO-292 (Selpercatinib)

    Time frame: Cycle 5 Day 1 (Cycle = 28 days)

  16. Phase 1: Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours

    Time frame: Cycle 1 Day 8: Predose, 1, 2, 4, 8, 24 hours post dose (cycle length = 28 days)

  17. Phase 1: Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax)

    Time frame: Cycle 1 Day 8: Predose, 1, 2, 4, 8, 24 hours post dose (cycle length = 28 days)

07

Results

Posted Apr 16, 2026

Participant flow

This study includes two parts: * Phase 1 (dose escalation) and; * Phase 2 (dose expansion) In Phase 1, participants received selpercatinib, with dosing based on body surface area. The Phase 2 portion of the study was opened after confirmation of the RP2D of 160 mg BID.

Phase 1 (Dose Escalation)
Participant flow — Phase 1 (Dose Escalation)
MilestonePhase 1: 20 mg Selpercatinib QDPhase 1: 20 mg Selpercatinib BIDPhase 1: 40 mg Selpercatinib BIDPhase 1: 60 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib QDPhase 1: 80 mg Selpercatinib BIDPhase 1: 120 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib BIDPhase 1: 200 mg Selpercatinib BIDPhase 1: 240 mg Selpercatinib BIDPhase 2, Cohort 1: RET Fusion Solid TumorPhase 2, Cohort 2: RET Fusion Solid Tumor Without Standard TherapyPhase 2, Cohort 3: RET Mutant MTCPhase 2, Cohort 4: RET Mutant MTC Without Standard TherapyPhase 2, Cohort 5: Advanced RET Altered Solid TumorPhase 2, Cohort 6: RET Inhibitor-Discontinued Participants
Started61016121201976436000000
Completed61016121201976436000000
Not completed0000000000000000
Phase 2 (Dose Expansion)
Participant flow — Phase 2 (Dose Expansion)
MilestonePhase 1: 20 mg Selpercatinib QDPhase 1: 20 mg Selpercatinib BIDPhase 1: 40 mg Selpercatinib BIDPhase 1: 60 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib QDPhase 1: 80 mg Selpercatinib BIDPhase 1: 120 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib BIDPhase 1: 200 mg Selpercatinib BIDPhase 1: 240 mg Selpercatinib BIDPhase 2, Cohort 1: RET Fusion Solid TumorPhase 2, Cohort 2: RET Fusion Solid Tumor Without Standard TherapyPhase 2, Cohort 3: RET Mutant MTCPhase 2, Cohort 4: RET Mutant MTC Without Standard TherapyPhase 2, Cohort 5: Advanced RET Altered Solid TumorPhase 2, Cohort 6: RET Inhibitor-Discontinued Participants
Started00000000003077414311620116
Completed0000000000000000
Not completed00000000003077414311620116
Withdrew: Ongoing000000000061214367586
Withdrew: Withdrawal by subject00000000003371311271
Withdrew: Lost to follow-up0000000000743341
Withdrew: Death0000000000147276718838
Withdrew: Sponsor's decision0000000000349512120
Withdrew: Moved to commercial supply of drug00000000001725030
Withdrew: Disease progression0000000000110110
Withdrew: Physician decision0000000000501010
Withdrew: Discontinued due to continued access00000000002212110
Withdrew: Alternative treatment therapy/soc drug0000000000012000
Withdrew: Enrolled for another trial0000000000002000
Withdrew: Participant's non-compliant0000000000001000
Withdrew: Participant unable to travel to site0000000000000100
Withdrew: Study transfer to derive more clinical benefit0000000000000100
Withdrew: Developed a secondary malignancy and is no longer qualified for this study0000000000000010

Outcome measures

PrimaryPhase 1: Maximum Tolerated Dose (MTD)

The MTD is defined as the highest dose level at which none of the first 3 treated patients, or not more than 1 of the first 6 treated patients, experiences a DLT. A DLT is any adverse events that starts on or after first administration of study drug, as defined by National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. * Any Grade(G) ≥3 nonhematologic toxicity, excluding * G3 AST, ALT, and/or total bilirubin elevation for \<7 days. * G3 neutropenia \<7 days * G3 thrombocytopenia without clinically significant bleeding * G3 or G4 lymphopenia. * First occurrence of G3 or G4 electrolyte abnormalities * G3 fatigue, weakness, nausea; other manageable constitutional symptom * G3 or G4 vomiting or diarrhea that lasts for \<48hours with antiemetic/antidiarrheal medication in case of G3 and \<24 hours in case of G4 * G4 manageable constitutional symptom.

Time frame:
Cycle 1 (cycle length = 28 days)
Reported as:
Number · milligrams
Phase 1: Maximum Tolerated Dose (MTD)
milligramsPhase 1 - Selpercatinib (All Participants)
Phase 1: Maximum Tolerated Dose (MTD)160
PrimaryPhase 1: Recommended Phase 2 Dose (RP2D)

Phase 1: RP2D

Time frame:
Cycle 1 (cycle length = 28 days)
Reported as:
Number · milligrams
Phase 1: Recommended Phase 2 Dose (RP2D)
milligramsPhase 1 - Selpercatinib (All Participants)
Phase 1: Recommended Phase 2 Dose (RP2D)160
PrimaryPhase 2: Objective Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment

Objective Response Rate was defined as the percentage of participants with best overall response of confirmed response (CR), or Partial response (PR). Response was confirmed by a repeat assessment no less than 28 days. * CR is defined as disappearance of all target lesions. * PR is defined as at least a 30% decrease in the sum of diameter (LD for non-nodal lesions and short axis diameter \[SAD\] for nodal lesions) of target lesions, taking as reference the baseline sum LD. ORR was assessed by independent review committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 95% confidence interval was calculated using Clopper-Pearson method.

Time frame:
Approximately for up to 7 years 8 months
Reported as:
Number · percentage of participants
Phase 2: Objective Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment
percentage of participantsPhase 2, Cohort 1: RET Fusion Solid TumorPhase 2, Cohort 2: RET Fusion Solid Tumor Without Standard TherapyPhase 2, Cohort 3: RET Mutant MTCPhase 2, Cohort 4: RET Mutant MTC Without Standard TherapyPhase 2, Cohort 5: Advanced RET Altered Solid TumorPhase 2, Cohort 6: RET Inhibitor-Discontinued Participants
Phase 2: Objective Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment62.9 (57.2 to 68.3)79.7 (68.8 to 88.2)77.6 (69.9 to 84.2)82.8 (74.6 to 89.1)57.2 (50.1 to 64.2)31.3 (11.0 to 58.7)
SecondaryPhase 1: Number of Participants With a Treatment-Related Adverse Event(s) (TRAE[s])

Phase 1: Number of Participants with a TRAE(s) is reported.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With a Treatment-Related Adverse Event(s) (TRAE[s])
ParticipantsPhase 1: 20 mg Selpercatinib QDPhase 1: 20 mg Selpercatinib BIDPhase 1: 40 mg Selpercatinib BIDPhase 1: 60 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib QDPhase 1: 80 mg Selpercatinib BIDPhase 1: 120 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib BIDPhase 1: 200 mg Selpercatinib BIDPhase 1: 240 mg Selpercatinib BID
Phase 1: Number of Participants With a Treatment-Related Adverse Event(s) (TRAE[s])3914121181773336
SecondaryPhase 1: Number of Participants With an Abnormal Laboratory Values
Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With an Abnormal Laboratory Values
ParticipantsPhase 1: 20 mg Selpercatinib QDPhase 1: 20 mg Selpercatinib BIDPhase 1: 40 mg Selpercatinib BIDPhase 1: 60 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib QDPhase 1: 80 mg Selpercatinib BIDPhase 1: 120 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib BIDPhase 1: 200 mg Selpercatinib BIDPhase 1: 240 mg Selpercatinib BID
Phase 1: Number of Participants With an Abnormal Laboratory Values61014121201976436
SecondaryPhase 2: Overall Response Rate (ORR) Based on RECIST 1.1 or RANO, as Appropriate to Tumor Type

Phase 2: ORR based on RECIST 1.1 or RANO, as Appropriate to Tumor Type

Time frame:
Approximately for up to 9 years 8 months

Results for this outcome have not been posted.

SecondaryPhase 2: ORR (by Investigator)

Phase 2: ORR (by Investigator)

Time frame:
Approximately for up to 9 years 8 months

Results for this outcome have not been posted.

SecondaryPhase 2: Best Change in Tumor Size From Baseline (by IRC and Investigator)

Phase 2: Best Change in Tumor Size from Baseline (by IRC and Investigator)

Time frame:
Approximately for up to 9 years 8 months

Results for this outcome have not been posted.

SecondaryPhase 2: Duration of Response (DOR; by IRC and Investigator)

Phase 2: DOR (by IRC and Investigator)

Time frame:
Approximately for up to 9 years 8 months

Results for this outcome have not been posted.

SecondaryPhase 2: Central Nervous System (CNS) ORR (by IRC)

Phase 2: CNS ORR (by IRC)

Time frame:
Approximately for up to 9 years 8 months

Results for this outcome have not been posted.

SecondaryPhase 2: CNS DOR (by IRC)

Phase 2: CNS DOR (by IRC)

Time frame:
Approximately for up to 9 years 8 months

Results for this outcome have not been posted.

SecondaryPhase 2: Time to Any and Best Response (by IRC and Investigator)

Phase 2: Time to Any and Best Response (by IRC and Investigator)

Time frame:
Approximately for up to 9 years 8 months

Results for this outcome have not been posted.

SecondaryPhase 2: CBR (by IRC and Investigator)

Phase 2: CBR (by IRC and Investigator)

Time frame:
Approximately for up to 9 years 8 months

Results for this outcome have not been posted.

SecondaryPhase 2: PFS (by IRC and Investigator)

Phase 2: PFS (by IRC and Investigator)

Time frame:
Approximately for up to 9 years 8 months

Results for this outcome have not been posted.

SecondaryPhase 2: Overall Survival (OS)

Phase 2: OS

Time frame:
Approximately for up to 9 years 8 months

Results for this outcome have not been posted.

SecondaryPhase 2: Percentage of Participants With Any Serious Adverse Event (SAE[s])

Phase 2: Percentage of Participants with any SAE(s)

Time frame:
Approximately for up to 9 years 8 months

Results for this outcome have not been posted.

SecondaryPhase 2: Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve of LOXO-292 (Selpercatinib)

Phase 2: PK: AUC of LOXO-292 (Selpercatinib)

Time frame:
Cycle 5 Day 1 (Cycle = 28 days)

Results for this outcome have not been posted.

SecondaryPhase 2: PK: Maximum Concentration (Cmax) of LOXO-292 (Selpercatinib)

Phase 2: PK: Cmax of LOXO-292 (Selpercatinib)

Time frame:
Cycle 5 Day 1 (Cycle = 28 days)

Results for this outcome have not been posted.

SecondaryPhase 1: Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours
Time frame:
Cycle 1 Day 8: Predose, 1, 2, 4, 8, 24 hours post dose (cycle length = 28 days)
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Phase 1: Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours
nanogram*hour per milliliter (ng*h/mL)Phase 1: 20 mg Selpercatinib QDPhase 1: 20 mg Selpercatinib BIDPhase 1: 40 mg Selpercatinib BIDPhase 1: 60 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib QDPhase 1: 80 mg Selpercatinib BIDPhase 1: 120 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib BIDPhase 1: 200 mg Selpercatinib BIDPhase 1: 240 mg Selpercatinib BID
Phase 1: Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours2240 ± 364570 ± 508450 ± 5317100 ± 46—19400 ± 4942200 ± 4053700 ± 53NA ± NA87900 ± 20
SecondaryPhase 1: Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax)
Time frame:
Cycle 1 Day 8: Predose, 1, 2, 4, 8, 24 hours post dose (cycle length = 28 days)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Phase 1: Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax)
nanogram per milliliter (ng/mL)Phase 1: 20 mg Selpercatinib QDPhase 1: 20 mg Selpercatinib BIDPhase 1: 40 mg Selpercatinib BIDPhase 1: 60 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib QDPhase 1: 80 mg Selpercatinib BIDPhase 1: 120 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib BIDPhase 1: 200 mg Selpercatinib BIDPhase 1: 240 mg Selpercatinib BID
Phase 1: Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax)220 ± 14275 ± 53528 ± 551040 ± 46—1250 ± 452680 ± 273080 ± 48NA ± NA5130 ± 17

Adverse events

Collected over Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: 20 mg Selpercatinib QD0/6 (0%)4/6 (66.7%)6/6 (100%)
Phase 1: 20 mg Selpercatinib BID0/10 (0%)8/10 (80%)10/10 (100%)
Phase 1: 40 mg Selpercatinib BID0/16 (0%)9/16 (56.3%)16/16 (100%)
Phase 1: 60 mg Selpercatinib BID0/12 (0%)7/12 (58.3%)12/12 (100%)
Phase 1: 160 mg Selpercatinib QD0/1 (0%)1/1 (100%)1/1 (100%)
Phase 1: 80 mg Selpercatinib BID0/20 (0%)13/20 (65%)20/20 (100%)
Phase 1: 120 mg Selpercatinib BID0/19 (0%)11/19 (57.9%)19/19 (100%)
Phase 1: 160 mg Selpercatinib BID0/764 (0%)380/764 (49.7%)764/764 (100%)
Phase 1: 200 mg Selpercatinib BID0/3 (0%)3/3 (100%)3/3 (100%)
Phase 1: 240 mg Selpercatinib BID0/6 (0%)3/6 (50%)6/6 (100%)
Phase 2, Cohort 1: RET Fusion Solid Tumor147/307 (47.9%)187/307 (60.9%)307/307 (100%)
Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy27/74 (36.5%)39/74 (52.7%)74/74 (100%)
Phase 2, Cohort 3: RET Mutant MTC67/143 (46.9%)93/143 (65%)143/143 (100%)
Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy18/116 (15.5%)65/116 (56%)116/116 (100%)
Phase 2, Cohort 5: Advanced RET Altered Solid Tumor83/201 (41.3%)114/201 (56.7%)201/201 (100%)
Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants8/16 (50%)8/16 (50%)16/16 (100%)
Most frequent serious events
Showing 10 of 420
Most frequent serious events
EventPhase 1: 20 mg Selpercatinib QDPhase 1: 20 mg Selpercatinib BIDPhase 1: 40 mg Selpercatinib BIDPhase 1: 60 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib QDPhase 1: 80 mg Selpercatinib BIDPhase 1: 120 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib BIDPhase 1: 200 mg Selpercatinib BIDPhase 1: 240 mg Selpercatinib BIDPhase 2, Cohort 1: RET Fusion Solid TumorPhase 2, Cohort 2: RET Fusion Solid Tumor Without Standard TherapyPhase 2, Cohort 3: RET Mutant MTCPhase 2, Cohort 4: RET Mutant MTC Without Standard TherapyPhase 2, Cohort 5: Advanced RET Altered Solid TumorPhase 2, Cohort 6: RET Inhibitor-Discontinued Participants
Blindness unilateralEye disorders0/60/100/160/121/10/200/190/7640/30/60/3070/741/1430/1160/2010/16
Blood bilirubin increasedInvestigations0/60/100/160/120/10/200/192/7642/30/61/3070/741/1430/1162/2010/16
EnterocolitisGastrointestinal disorders0/60/100/160/120/110/200/193/7640/30/62/3070/740/1430/1161/2010/16
Abdominal painGastrointestinal disorders2/61/101/160/120/12/201/1921/7640/30/67/3071/744/1434/11612/2010/16
AscitesGastrointestinal disorders2/60/100/161/120/11/201/1911/7640/30/67/3070/745/1432/1162/2010/16
CholecystitisHepatobiliary disorders1/60/100/160/120/10/200/196/7641/30/62/3070/741/1432/1163/2010/16
Alanine aminotransferase increasedInvestigations0/60/101/160/120/10/200/199/7641/30/65/3071/740/1431/1164/2010/16
Aspartate aminotransferase increasedInvestigations0/60/101/160/120/10/200/199/7641/30/65/3071/740/1431/1164/2010/16
Blood alkaline phosphatase increasedInvestigations0/60/100/160/120/10/200/190/7641/30/60/3070/740/1430/1161/2010/16
Blood creatine phosphokinase increasedInvestigations0/60/100/160/120/10/200/190/7641/30/60/3070/741/1430/1160/2010/16
Most frequent other events
Showing 10 of 284
Most frequent other events
EventPhase 1: 20 mg Selpercatinib QDPhase 1: 20 mg Selpercatinib BIDPhase 1: 40 mg Selpercatinib BIDPhase 1: 60 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib QDPhase 1: 80 mg Selpercatinib BIDPhase 1: 120 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib BIDPhase 1: 200 mg Selpercatinib BIDPhase 1: 240 mg Selpercatinib BIDPhase 2, Cohort 1: RET Fusion Solid TumorPhase 2, Cohort 2: RET Fusion Solid Tumor Without Standard TherapyPhase 2, Cohort 3: RET Mutant MTCPhase 2, Cohort 4: RET Mutant MTC Without Standard TherapyPhase 2, Cohort 5: Advanced RET Altered Solid TumorPhase 2, Cohort 6: RET Inhibitor-Discontinued Participants
Blindness unilateralEye disorders0/60/100/160/121/10/200/190/7640/30/60/3070/741/1430/1160/2010/16
Periorbital oedemaEye disorders0/62/101/161/121/10/202/1958/7640/30/621/3074/7411/14312/11616/2011/16
Abdominal distensionGastrointestinal disorders3/60/101/162/121/15/205/19110/7640/32/636/3076/7428/14328/11630/2011/16
AscitesGastrointestinal disorders2/61/101/163/121/12/203/19121/7640/31/649/3077/7424/14324/11629/2012/16
DiarrhoeaGastrointestinal disorders3/65/107/165/121/19/2012/19394/7641/33/6169/30732/7467/14361/116102/2019/16
VomitingGastrointestinal disorders2/66/105/162/121/16/204/19214/7642/32/682/30721/7447/14334/11657/2013/16
Face oedemaGeneral disorders0/61/101/161/121/10/202/1986/7641/30/645/3076/7414/1438/11620/2010/16
FatigueGeneral disorders3/66/1011/164/121/17/2010/19298/7643/33/6111/30731/7456/14364/11680/2014/16
Oedema peripheralGeneral disorders4/66/104/163/121/19/208/19284/7641/32/6121/30720/7464/14342/11669/2016/16
Blood creatinine increasedInvestigations0/61/103/162/121/15/203/19225/7640/31/678/30715/7440/14354/11650/2014/16

Baseline characteristics

All enrolled Participants.

Age, Categorical
Age, Categorical(Participants)Phase 1: 20 mg Selpercatinib QDPhase 1: 20 mg Selpercatinib BIDPhase 1: 40 mg Selpercatinib BIDPhase 1: 60 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib QDPhase 1: 80 mg Selpercatinib BIDPhase 1: 120 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib BIDPhase 1: 200 mg Selpercatinib BIDPhase 1: 240 mg Selpercatinib BIDTotal
<=18 years00000102003
Between 18 and 65 years561190111349524556
>=65 years145318626712298
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: 20 mg Selpercatinib QDPhase 1: 20 mg Selpercatinib BIDPhase 1: 40 mg Selpercatinib BIDPhase 1: 60 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib QDPhase 1: 80 mg Selpercatinib BIDPhase 1: 120 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib BIDPhase 1: 200 mg Selpercatinib BIDPhase 1: 240 mg Selpercatinib BIDTotal
Female4575071037814421
Male2597113938622436
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: 20 mg Selpercatinib QDPhase 1: 20 mg Selpercatinib BIDPhase 1: 40 mg Selpercatinib BIDPhase 1: 60 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib QDPhase 1: 80 mg Selpercatinib BIDPhase 1: 120 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib BIDPhase 1: 200 mg Selpercatinib BIDPhase 1: 240 mg Selpercatinib BIDTotal
Hispanic or Latino0100001380040
Not Hispanic or Latino6915121201870036790
Unknown or Not Reported0010000260027
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1: 20 mg Selpercatinib QDPhase 1: 20 mg Selpercatinib BIDPhase 1: 40 mg Selpercatinib BIDPhase 1: 60 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib QDPhase 1: 80 mg Selpercatinib BIDPhase 1: 120 mg Selpercatinib BIDPhase 1: 160 mg Selpercatinib BIDPhase 1: 200 mg Selpercatinib BIDPhase 1: 240 mg Selpercatinib BIDTotal
American Indian or Alaska Native00000002002
Asian101102319801207
Native Hawaiian or Other Pacific Islander00000002002
Black or African American0021000240027
White51013101161550235580
More than one race00000000000
Unknown or Not Reported0000021360039
08

Study locations

85 sites
09

References and documents

Publications

  • Gautschi O, Park K, Solomon BJ, Tomasini P, Loong HH, De Braud F, Goto K, Peterson P, Barker S, Liming K, Oxnard GR, Frimodt-Moller B, Drilon A. Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial. J Clin Oncol. 2025 May 20;43(15):1758-1764. doi: 10.1200/JCO-24-02076. Epub 2025 Feb 21. PubMed 39983053 ↗
  • Raez LE, Massey AC, Barker SS, Peterson PM, Liming K, Pennell NA. Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time. Oncologist. 2024 Dec 6;29(12):1068-1078. doi: 10.1093/oncolo/oyae282. PubMed 39471424 ↗
  • Wirth LJ, Brose MS, Subbiah V, Worden F, Solomon B, Robinson B, Hadoux J, Tomasini P, Weiler D, Deschler-Baier B, Tan DSW, Maeda P, Lin Y, Singh R, Bayt T, Drilon A, Cassier PA. Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. J Clin Oncol. 2024 Sep 20;42(27):3187-3195. doi: 10.1200/JCO.23.02503. Epub 2024 Aug 2. PubMed 39094065 ↗
  • Deschler-Baier B, Krebs M, Kroiss M, Chatterjee M, Gundel D, Kestler C, Kerscher A, Kunzmann V, Appenzeller S, Maurus K, Rosenwald A, Bargou R, Gerhard-Hartmann E, Venkataramani V. Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch. NPJ Precis Oncol. 2024 Jul 31;8(1):167. doi: 10.1038/s41698-024-00659-x. PubMed 39085487 ↗
  • Deschler-Baier B, Konda B, Massarelli E, Hu MI, Wirth LJ, Xu X, Wright J, Clifton-Bligh RJ. Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma. J Clin Endocrinol Metab. 2025 Feb 18;110(3):e600-e606. doi: 10.1210/clinem/dgae283. PubMed 38661071 ↗
  • Subbiah V, Burris HA 3rd, Kurzrock R. Revolutionizing cancer drug development: Harnessing the potential of basket trials. Cancer. 2024 Jan;130(2):186-200. doi: 10.1002/cncr.35085. Epub 2023 Nov 7. PubMed 37934000 ↗
  • Duke ES, Bradford D, Marcovitz M, Amatya AK, Mishra-Kalyani PS, Nguyen E, Price LSL, Fourie Zirkelbach J, Li Y, Bi Y, Kraft J, Dorff SE, Scepura B, Stephenson M, Ojofeitimi I, Nair A, Han Y, Tezak Z, Lemery SJ, Pazdur R, Larkins E, Singh H. FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors. Clin Cancer Res. 2023 Sep 15;29(18):3573-3578. doi: 10.1158/1078-0432.CCR-23-0459. PubMed 37265412 ↗
  • Murciano-Goroff YR, Falcon CJ, Lin ST, Chacko C, Grimaldi G, Liu D, Wilhelm C, Iasonos A, Drilon A. Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib. J Thorac Oncol. 2023 May;18(5):620-627. doi: 10.1016/j.jtho.2023.01.008. Epub 2023 Jan 16. PubMed 36657661 ↗
  • Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, Shao-Weng Tan D, Alonso G, Wolf J, Park K, Goto K, Soldatenkova V, Szymczak S, Barker SS, Puri T, Bence Lin A, Loong H, Besse B. Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. J Clin Oncol. 2023 Jan 10;41(2):385-394. doi: 10.1200/JCO.22.00393. Epub 2022 Sep 19. PubMed 36122315 ↗
  • Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: 10.1016/S1470-2045(22)00541-1. Epub 2022 Sep 12. PubMed 36108661 ↗
  • Rolfo C, Hess LM, Jen MH, Peterson P, Li X, Liu H, Lai Y, Sugihara T, Kiiskinen U, Vickers A, Summers Y. External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer. ESMO Open. 2022 Aug;7(4):100551. doi: 10.1016/j.esmoop.2022.100551. Epub 2022 Aug 2. PubMed 35930972 ↗
  • Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong HH, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, Rolfo C, Zhu EY, Kherani JF, Huang X, Kang S, Drilon A. Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. Clin Cancer Res. 2021 Aug 1;27(15):4160-4167. doi: 10.1158/1078-0432.CCR-21-0800. Epub 2021 Jun 4. PubMed 34088726 ↗
  • Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardiere C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 Aug 27;383(9):825-835. doi: 10.1056/NEJMoa2005651. PubMed 32846061 ↗
  • Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Aug 27;383(9):813-824. doi: 10.1056/NEJMoa2005653. PubMed 32846060 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Feb 2025, 93 months.

Results were first posted in Apr 2026, 1 year 2 months after primary completion.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 93 months is above that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2017
First posted
May 17, 2017
StartActual
May 2, 2017
Primary completionActual
Feb 14, 2025
CompletionEst.
Feb 2027
Results first posted
Apr 16, 2026
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03157128
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
May 17, 2017
Start date
May 2, 2017
Primary completion
Feb 14, 2025
Completion
Feb 2027 (estimated)
Results posted
Apr 16, 2026
Last update
Apr 16, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selpercatinib

Start the discussion